procter & gamble co/the (PG) Key Developments
Procter & Gamble To Sell Its Pets Care Business
Apr 9 14
The Procter & Gamble Company (NYSE:PG) is planning to sell its pets care business in Europe. Alan Lafley, Chief Executive Officer of Procter & Gamble, said, "Exiting pet care is an important step in our strategy to focus on P&G's portfolio on the core businesses where we can create the most value for consumers and shareowners."
The Procter & Gamble Company Declares Increase in the Quarterly Dividend on its Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock Payable on or After May 15, 2014
Apr 7 14
The Procter & Gamble Company announced that its Board of Directors declared an increase in the quarterly dividend from $0.6015 to $0.6436 per share on its Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after May 15, 2014, to Common Stock shareholders of record at the close of business on April 25, 2014, and to Series A and Series B Preferred Stock shareholders of record at the start of business on April 25, 2014. This represents a 7% increase compared to the prior quarterly dividend.
Olay Reformulates its Regenerist Line with New Skin Energizing Technology
Mar 6 14
Olay announced that it has reformulated its Regenerist line with new Skin Energizing Technology -- a hydrating formula designed to improve skin's responsiveness to anti-aging ingredients and fight the look of skin fatigue by accelerating surface layer cell turnover, increasing brightness and decreasing the appearance of fine lines and wrinkles. The reformulated Olay Regenerist line includes the Micro-Sculpting Cream, Micro-Sculpting Eye Cream & Lash Duo, Advanced Anti-Aging Wrinkle Revolution Complex and Micro-Sculpting Serum. All are available in retailers nationwide at a suggested retail price between $25.99 and $33.99.
The Procter & Gamble Company Selects Henry Schein, Inc. as Exclusive Veterinary Distributor of Iams(R) Therapeutic Diet Formulas
Feb 26 14
The Procter & Gamble Company and Henry Schein, Inc. announced a new agreement under which Henry Schein will be the exclusive distributor of P&G's Iams(R) therapeutic diet formulas to veterinary practices in the contiguous United States. Under the new agreement, Henry Schein Animal Health, the U.S. animal health division of Henry Schein, will be the exclusive distributor of Iams' therapeutic line of dog and cat food solutions, including special formulas to help nutritionally manage pet health concerns such as digestive imbalance, skin & coat, weight management and joint and urinary issues. Henry Schein will distribute the Iams' therapeutic and wellness diets as part of a complete portfolio of pet nutritional solutions it offers to veterinarians throughout the United States.
P&G Reportedly Plans To Divest MDVIP Unit
Feb 24 14
The Procter & Gamble Company (NYSE:PG) (P&G) is known to be looking at divesting its MDVIP concierge business unit. Last week the company reaffirmed that it would exit ventures that won’t help it grow. The Wall Street Journal reported citing unnamed sources that P&G has retained Piper Jaffray & Co. as its adviser on the sale.